What will happen now in the statin drugs market'What does the future hold for the statins industry and market' Our new report shows how the patent expiry of Lipitor and others will affect statin drug revenues from 2011 onwards.Our report gives you revenue forecasts for statin drugs from 2011 to 2021. We aim to save you time and aid your decisions through our research, data and discussions. By ordering now, you can stay ahead.In 2009 the world statins market generated over $27bn in revenues. We show the organisations, products and activities that will shape the statins industry and market this decade.
This document discusses hypertension in India. It provides statistics on the prevalence and burden of hypertension globally and within India. Some key points:
- Over a billion adults globally had hypertension in 2000, predicted to rise to 1.56 billion by 2025. Prevalence is increasing fastest in developing countries.
- In India, prevalence has risen from 2-15% in the 1990s to over 25% in urban areas and 10-15% in rural areas currently. By 2020, an estimated 159.46 per 1000 population will have hypertension.
- Hypertension awareness, treatment and control is low in India, with only around half of urban and a quarter of rural hypertensive individuals aware of their condition. Pro
Smartphones: When is the first and last time you check yours?ReportLinker.com
Nearly half (46%) of Americans say they check their smartphones as soon as they wake up, while they’re still in bed, according to ReportLinker’s survey results. This is especially true of Millennials, 66% of whom say it’s the first thing they do before getting out of bed.
75% of Ameircans say they keep their smartphones active all day and night, and a staggering 83% of Millennials say they do.
In fact, disconnecting can be hard. More than half of Americans say their last check is right before bed – and 13% say they disconnect only after they’ve gotten into bed for the night. Even after they fall asleep, about 10% say they’ll wake up and check it during the night.
Interview Co-Founder ReportLinker and Findout, Benjamin CarpanoReportLinker.com
ReportLinker and Findout use data analytics technologies to aggregate and normalize data from a wide range of sources to help researchers and analysts find relevant information more efficiently. The companies' core competency lies in both search and data analytics capabilities. Their natural language processing platform analyzes millions of documents daily to extract and structure concepts, relationships, and sentiments to improve users' productivity. Open data initiatives have helped the businesses by providing more content to incorporate, though most value comes from backend processing rather than raw data access. The companies aim to continue enhancing data discovery and contextualization of results.
This graphic shows Samsung's customers are still loyal: 86% of Samsung Customers would consider Samsung next time they upgrade their smartphone. More info on reportlinker.com/inisght
This document provides a summary of a report on the European branded coffee shop market in 23 countries. Some key points:
- It examines the size and growth of the branded coffee shop market in each country from 2009-2015. Several countries like Poland and Spain saw strong growth over 10% in 2011-2012.
- Market leaders like Starbucks, Costa Coffee and Coffee Fellows are profiled for each country along with operating statistics and strategies. Consumer trends toward convenience and sustainability are also discussed.
- Challenges facing the industry like economic uncertainty and high rents are analyzed. Success factors include quality coffee, food offerings and a strong brand. The growth potential of each market is evaluated based on GDP per capita and existing
Allegra's definitive annual study on the UK branded coffee shop market is now available; with insight from over 25,000 consumers the report provides an authoritative view of the market.Drawing on more than 12 years in-depth research, it is considered to be the bible of the coffee sector.KEY AREAS COVERED' Market size and growth projections for the total UK market' Impact of recent economic downturn on trading performance' Key player profiles, including financial performance, pricing analysis and forecasts' Importance of ethical and sustainability issues' Key success factors and market trends' Opportunities and challenges for suppliers' Consumer coffee consumption patterns' Consumer brand awareness and perceptions of key players' Differences between customer demographics, including age, gender, occupation and location by the reportSOURCE OF INFORMATION' Interviews with CEOs, managing directors, senior managers and store managers of major industry players, including:' leading UK coffee and food-focused chains' major coffee roasters and key equipment suppliers' non-specialist players including department stores, supermarkets, bookstores' leading property companies, letting agents and landlords' local authorities' Online surveys with UK coffee shop visitors' Desk research including: News articles and trade press, the Internet and company websites,industry associations, published accounts, data supplied by operators' In-store observations and analysis
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...ReportLinker.com
WinterGreen Research announces that it has published a new study Wireless Infrastructure: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. Next generation mission critical systems are leveraging new technology. The 2013 study has 554 pages, 245 tables and figures. Worldwide Wireless Infrastructure markets are poised to achieve significant growth as Building out core networks and backhaul for smart phones.A smart phone is not very smart if the infrastructure can't support its applications. In response to the high growth smart phone markets, wireless infrastructure promises to grow dramatically in the near term.. Wireless Infrastructure technologies include WiMax, LTE, 4G and HSPA. These technologies are driving much higher capacity from the base station back to the fiber core. Fiber core is putting extreme pressure on provider's infrastructure and backhaul networks.WinterGreen Research predicts that the dramatic growth of wireless infrastructure is based on the growth of smart phones to a one trillion market by 2019, serving an installed base of 8.5 billion, many people having more than one smart phone. Wireless infrastructure markets at $58 billion in 2012 will be $163 billion by 2019, new markets evolved because of the value that apps provide to smart phones, mobile devices, tablets, and the Internet of things.According to Susan Eustis, lead author of the study, 'Wireless Infrastructure is being installed to upgrade core networks and upgrade backhaul and base stations to make systems more modern. Infrastructure for the Internet and for smart mobile devices creates demand for more sophisticated web development and web applications that in turn depend on more sophisticated infrastructure. Everything is going mobile. This evolution is driven by mobile smart phones and tablets that provide universal connectivity. Modern systems represent a significant aspect of Internet market evolution.'The proportions of wireless infrastructure market industry segments are expected to remain much as they are, with the small cells and femtocells achieving strong growth on the access side, the core infrastructure must be upgraded to support the added backhaul backbone infrastructure. Wireless apps are expected to achieve $37 trillion revenue by 2019. This unbelievable growth occurs as the Internet is expanded to implement the interconnection of everything.Digital devices proliferate, machine to machine capabilities vastly expand instrumentation. The digital devices become the engine of a world economy, with apps collecting pennies a day for millions of apps from 8.5 billion people with smart phones by 2019.
This document discusses hypertension in India. It provides statistics on the prevalence and burden of hypertension globally and within India. Some key points:
- Over a billion adults globally had hypertension in 2000, predicted to rise to 1.56 billion by 2025. Prevalence is increasing fastest in developing countries.
- In India, prevalence has risen from 2-15% in the 1990s to over 25% in urban areas and 10-15% in rural areas currently. By 2020, an estimated 159.46 per 1000 population will have hypertension.
- Hypertension awareness, treatment and control is low in India, with only around half of urban and a quarter of rural hypertensive individuals aware of their condition. Pro
Smartphones: When is the first and last time you check yours?ReportLinker.com
Nearly half (46%) of Americans say they check their smartphones as soon as they wake up, while they’re still in bed, according to ReportLinker’s survey results. This is especially true of Millennials, 66% of whom say it’s the first thing they do before getting out of bed.
75% of Ameircans say they keep their smartphones active all day and night, and a staggering 83% of Millennials say they do.
In fact, disconnecting can be hard. More than half of Americans say their last check is right before bed – and 13% say they disconnect only after they’ve gotten into bed for the night. Even after they fall asleep, about 10% say they’ll wake up and check it during the night.
Interview Co-Founder ReportLinker and Findout, Benjamin CarpanoReportLinker.com
ReportLinker and Findout use data analytics technologies to aggregate and normalize data from a wide range of sources to help researchers and analysts find relevant information more efficiently. The companies' core competency lies in both search and data analytics capabilities. Their natural language processing platform analyzes millions of documents daily to extract and structure concepts, relationships, and sentiments to improve users' productivity. Open data initiatives have helped the businesses by providing more content to incorporate, though most value comes from backend processing rather than raw data access. The companies aim to continue enhancing data discovery and contextualization of results.
This graphic shows Samsung's customers are still loyal: 86% of Samsung Customers would consider Samsung next time they upgrade their smartphone. More info on reportlinker.com/inisght
This document provides a summary of a report on the European branded coffee shop market in 23 countries. Some key points:
- It examines the size and growth of the branded coffee shop market in each country from 2009-2015. Several countries like Poland and Spain saw strong growth over 10% in 2011-2012.
- Market leaders like Starbucks, Costa Coffee and Coffee Fellows are profiled for each country along with operating statistics and strategies. Consumer trends toward convenience and sustainability are also discussed.
- Challenges facing the industry like economic uncertainty and high rents are analyzed. Success factors include quality coffee, food offerings and a strong brand. The growth potential of each market is evaluated based on GDP per capita and existing
Allegra's definitive annual study on the UK branded coffee shop market is now available; with insight from over 25,000 consumers the report provides an authoritative view of the market.Drawing on more than 12 years in-depth research, it is considered to be the bible of the coffee sector.KEY AREAS COVERED' Market size and growth projections for the total UK market' Impact of recent economic downturn on trading performance' Key player profiles, including financial performance, pricing analysis and forecasts' Importance of ethical and sustainability issues' Key success factors and market trends' Opportunities and challenges for suppliers' Consumer coffee consumption patterns' Consumer brand awareness and perceptions of key players' Differences between customer demographics, including age, gender, occupation and location by the reportSOURCE OF INFORMATION' Interviews with CEOs, managing directors, senior managers and store managers of major industry players, including:' leading UK coffee and food-focused chains' major coffee roasters and key equipment suppliers' non-specialist players including department stores, supermarkets, bookstores' leading property companies, letting agents and landlords' local authorities' Online surveys with UK coffee shop visitors' Desk research including: News articles and trade press, the Internet and company websites,industry associations, published accounts, data supplied by operators' In-store observations and analysis
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...ReportLinker.com
WinterGreen Research announces that it has published a new study Wireless Infrastructure: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. Next generation mission critical systems are leveraging new technology. The 2013 study has 554 pages, 245 tables and figures. Worldwide Wireless Infrastructure markets are poised to achieve significant growth as Building out core networks and backhaul for smart phones.A smart phone is not very smart if the infrastructure can't support its applications. In response to the high growth smart phone markets, wireless infrastructure promises to grow dramatically in the near term.. Wireless Infrastructure technologies include WiMax, LTE, 4G and HSPA. These technologies are driving much higher capacity from the base station back to the fiber core. Fiber core is putting extreme pressure on provider's infrastructure and backhaul networks.WinterGreen Research predicts that the dramatic growth of wireless infrastructure is based on the growth of smart phones to a one trillion market by 2019, serving an installed base of 8.5 billion, many people having more than one smart phone. Wireless infrastructure markets at $58 billion in 2012 will be $163 billion by 2019, new markets evolved because of the value that apps provide to smart phones, mobile devices, tablets, and the Internet of things.According to Susan Eustis, lead author of the study, 'Wireless Infrastructure is being installed to upgrade core networks and upgrade backhaul and base stations to make systems more modern. Infrastructure for the Internet and for smart mobile devices creates demand for more sophisticated web development and web applications that in turn depend on more sophisticated infrastructure. Everything is going mobile. This evolution is driven by mobile smart phones and tablets that provide universal connectivity. Modern systems represent a significant aspect of Internet market evolution.'The proportions of wireless infrastructure market industry segments are expected to remain much as they are, with the small cells and femtocells achieving strong growth on the access side, the core infrastructure must be upgraded to support the added backhaul backbone infrastructure. Wireless apps are expected to achieve $37 trillion revenue by 2019. This unbelievable growth occurs as the Internet is expanded to implement the interconnection of everything.Digital devices proliferate, machine to machine capabilities vastly expand instrumentation. The digital devices become the engine of a world economy, with apps collecting pennies a day for millions of apps from 8.5 billion people with smart phones by 2019.
This document is a fax order form for reports from ReportLinker, which provides industry reports, company profiles, and market statistics. It contains fields for customers to provide contact and billing information as well as select a payment method of credit card, wire transfer, or check in order to place an order for reports. The form directs customers to fax the completed form back to ReportLinker offices in either Europe, the Middle East, and Africa or Asia, Oceania, and America depending on location.
This document is a fax order form for industry reports and company profiles from ReportLinker. It contains fields for customers to provide their contact and shipping information as well as payment details including credit card number, expiration date, and CVV. The form also lists ReportLinker's fax numbers for customers in different regions to submit their orders.
This very short document contains a single word - "TEST" - with no other context provided. It is not possible to provide a meaningful summary in 3 sentences or less given the extremely limited information.
Global Electric Resistance Welded Pipes IndustryReportLinker.com
This report analyzes the worldwide markets for Electric Resistance Welded Pipes in Thousand Tons by the following Product Segments: Mechanical Steel Tubing, Structural Tubing, Structural Steel Pipes, Pressure Tubing, Standard Pipes, Oil Country Tubular Goods, and Line Pipes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 181 companies including many key and niche players such as Al Jazeera Steel Products Company SAOG, Arabian Pipes Company, ArcelorMittal SA, ERW Pipes Portfolio of ArcelorMittal ChelPipe, Choo Bee Metal Industries Berhad, EVRAZ North America, JFE Steel Corporation, Maharashtra Seamless Limited, Melewar Industrial Group Berhad, Nippon Steel & Sumitomo Metal Corporation, Northwest Pipe Company, OAO TMK, TMK IPSCO, PT Bakrie Pipe Industries, Salzgitter Mannesmann Line Pipe GmbH, Tata Steel Europe, Techint Group SpA, Tenaris S.A., TenarisSiderca, Ternium S.A., United States Steel Corporation, United Metallurgical Company /OMK, Welspun Corp Ltd., Wheatland Tube Company, and Select Products of Wheatland Tube Company. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
This report analyzes the worldwide markets for Wireless Gaming in US$ Million by the following Product Segments: Messaging Based Wireless Gaming, Browser/Web Based Wireless Gaming, and Downloadable Wireless Gaming. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. The report profiles 90 companies including many key and niche players such as Blockdot, Inc., DeNA Co., Ltd., Electronic Arts, Inc., Gameloft SA,GAMEVIL, GREE International, Inc., Glu Mobile Inc., GigaMedia Limited, HandyGames, I-play, Itsmy
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
Overview: There are a number of technologies that may be deployed that all provide the ability for devices to "discover" one another, although over different distances ranging from centimeters (Near Field Communications), to meters (Bluetooth), to 10s of meters (Wi-Fi). They also all provide the ability for the devices to communicate directly with one another without a centralized network. Some of these use direct communication as their primary mode of communication e.g. NFC or RFID. Others are more traditional networks which provide direct communication ability as an adjunct to their primary network functions e.g. LTE-Direct or Wi-Fi Direct. Most of the short-term drivers for proximity-based services will be mobile advertising and social networking, especially friend-finder services or dating services, and gaming. In the longer term, other applications will come into play within the scope of the so called Internet of Things. The challenge and opportunity for network operators will be to develop new user scenarios and even new business models to generate revenues from these services. This research uncovers opportunities that will be both beneficial and disruptive to the existing ecosystem and value chain. This research is must reading for any company that is considering offerings within proximity and direct communications and any company that wants to stay ahead of the crowd in terms of preparation for these disruptive technologies. Target Audience: ' Mobile network operators' Industry verticals of all types' Wireless device manufacturers' Network infrastructure companies' Advertising agencies, brands, and merchants' Social networks, advertising, and content providers' Proximity, location, and direct communications vendors Key Report Benefits: ' Market forecasts for each significant technology/solution approach' Recognize the upcoming role and importance of LTE Direct compared to other solutions' Analysis of the major vendors focused on proximity and direct communications solutions' Understand the relationship between proximity, direct communications and the Internet of Things' Understand the technical and business-related differences between proximity/presence and location' Identify each of the major technologies/solutions for proximity detection, location determination, and direct communications' Evaluation of the market for major applications including public safety, social networking, advertising, the Internet of Things, and general location services Select Companies in Report: ' 3M Company' Alcatel-Lucent' iSIGN' LG' Nokia' Samsung' Qualcomm' Verizon Wireless
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This document provides a summary and table of contents for a 900-page report analyzing the clinical chemistry and immunodiagnostic markets in five major European countries. The report explores trends, evaluates competitors, and identifies opportunities in these evolving markets. It contains estimates of test volumes, sales forecasts by category and country, and competitive profiles of leading suppliers.
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
This document is a report on the China iron ore mining industry in 2013. It provides an overview of the industry, including its definition and development history. It analyzes the macroeconomic environment and discusses factors like policy, upstream/downstream industries. It also examines the international and domestic markets. Key data on the industry from 2008-2012 is presented, including numbers of enterprises, employees, assets, output, sales, profits and trade. The competitive landscape and strategies of major companies are evaluated. The report concludes with discussions of development trends, investment environment and new technologies in the industry.
This document provides a summary and table of contents of the "World Biomass Report" published in November 2012. The report examines the global biomass market and finds that while it suffered during the economic downturn due to low coal prices and supply issues, the sector began growing again in 2010 as coal prices rose. Most biomass plants rely on wood pellets imported from North America, though suppliers from other regions like Russia and Australia aim to compete in the market. The full report contains detailed information on biomass resources, technologies, logistics, investments and policies on a global and national level.
This report provides an overview of the global biofuels industry in 2012. It summarizes production and policies related to first, second, and third generation biofuels in countries around the world. The report finds that 2009 was a difficult year for the biofuels industry due to low oil prices and reduced demand. However, projects using diverse feedstocks or next generation technologies like cellulosics and algae continued to receive investment. The report includes sections on biofuel production trends, technologies, environmental impacts, and policies in regions like Europe, the USA, and individual European countries.
This report analyzes the current state of various renewable energy technologies including hydropower, wind, solar, biomass, biofuels, and geothermal. It examines the market size and outlook for each technology by region, discusses the advantages and disadvantages of different renewable sources, and assesses the development status and future potential of the renewable energy industry globally. The report also profiles major renewable energy companies and evaluates government policies and industry support programs around the world.
This report provides an overview of the global solar photovoltaic (PV) market. It outlines key industry data like global solar capacity, production figures, and forecasts for future growth. It also examines major country markets and discusses the advantages, challenges, and components of the solar PV industry. The report analyzes factors such as government incentives, technology developments, and manufacturing trends that are shaping the future of the solar industry.
Inguinal Hernia Global Clinical Trials Review, H1, 2013ReportLinker.com
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Inguinal Hernia Global Clinical Trials Review, H1, 2013" provides data on the Inguinal Hernia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inguinal Hernia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Inguinal Hernia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Cancer Cachexia Global Clinical Trials Review, H1, 2013" provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Cachexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Pompe Disease Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report on clinical trials for Pompe disease from January 2013. It provides an overview of the number and location of trials worldwide in the first half of 2013. The US, Germany, and China had the most trials. The trials were mostly in late phases and investigated drugs from companies like Genzyme and Sanofi. The report analyzed trial trends over time and provided profiles of top trial sponsors.
This document is a fax order form for reports from ReportLinker, which provides industry reports, company profiles, and market statistics. It contains fields for customers to provide contact and billing information as well as select a payment method of credit card, wire transfer, or check in order to place an order for reports. The form directs customers to fax the completed form back to ReportLinker offices in either Europe, the Middle East, and Africa or Asia, Oceania, and America depending on location.
This document is a fax order form for industry reports and company profiles from ReportLinker. It contains fields for customers to provide their contact and shipping information as well as payment details including credit card number, expiration date, and CVV. The form also lists ReportLinker's fax numbers for customers in different regions to submit their orders.
This very short document contains a single word - "TEST" - with no other context provided. It is not possible to provide a meaningful summary in 3 sentences or less given the extremely limited information.
Global Electric Resistance Welded Pipes IndustryReportLinker.com
This report analyzes the worldwide markets for Electric Resistance Welded Pipes in Thousand Tons by the following Product Segments: Mechanical Steel Tubing, Structural Tubing, Structural Steel Pipes, Pressure Tubing, Standard Pipes, Oil Country Tubular Goods, and Line Pipes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 181 companies including many key and niche players such as Al Jazeera Steel Products Company SAOG, Arabian Pipes Company, ArcelorMittal SA, ERW Pipes Portfolio of ArcelorMittal ChelPipe, Choo Bee Metal Industries Berhad, EVRAZ North America, JFE Steel Corporation, Maharashtra Seamless Limited, Melewar Industrial Group Berhad, Nippon Steel & Sumitomo Metal Corporation, Northwest Pipe Company, OAO TMK, TMK IPSCO, PT Bakrie Pipe Industries, Salzgitter Mannesmann Line Pipe GmbH, Tata Steel Europe, Techint Group SpA, Tenaris S.A., TenarisSiderca, Ternium S.A., United States Steel Corporation, United Metallurgical Company /OMK, Welspun Corp Ltd., Wheatland Tube Company, and Select Products of Wheatland Tube Company. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
This report analyzes the worldwide markets for Wireless Gaming in US$ Million by the following Product Segments: Messaging Based Wireless Gaming, Browser/Web Based Wireless Gaming, and Downloadable Wireless Gaming. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. The report profiles 90 companies including many key and niche players such as Blockdot, Inc., DeNA Co., Ltd., Electronic Arts, Inc., Gameloft SA,GAMEVIL, GREE International, Inc., Glu Mobile Inc., GigaMedia Limited, HandyGames, I-play, Itsmy
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
Overview: There are a number of technologies that may be deployed that all provide the ability for devices to "discover" one another, although over different distances ranging from centimeters (Near Field Communications), to meters (Bluetooth), to 10s of meters (Wi-Fi). They also all provide the ability for the devices to communicate directly with one another without a centralized network. Some of these use direct communication as their primary mode of communication e.g. NFC or RFID. Others are more traditional networks which provide direct communication ability as an adjunct to their primary network functions e.g. LTE-Direct or Wi-Fi Direct. Most of the short-term drivers for proximity-based services will be mobile advertising and social networking, especially friend-finder services or dating services, and gaming. In the longer term, other applications will come into play within the scope of the so called Internet of Things. The challenge and opportunity for network operators will be to develop new user scenarios and even new business models to generate revenues from these services. This research uncovers opportunities that will be both beneficial and disruptive to the existing ecosystem and value chain. This research is must reading for any company that is considering offerings within proximity and direct communications and any company that wants to stay ahead of the crowd in terms of preparation for these disruptive technologies. Target Audience: ' Mobile network operators' Industry verticals of all types' Wireless device manufacturers' Network infrastructure companies' Advertising agencies, brands, and merchants' Social networks, advertising, and content providers' Proximity, location, and direct communications vendors Key Report Benefits: ' Market forecasts for each significant technology/solution approach' Recognize the upcoming role and importance of LTE Direct compared to other solutions' Analysis of the major vendors focused on proximity and direct communications solutions' Understand the relationship between proximity, direct communications and the Internet of Things' Understand the technical and business-related differences between proximity/presence and location' Identify each of the major technologies/solutions for proximity detection, location determination, and direct communications' Evaluation of the market for major applications including public safety, social networking, advertising, the Internet of Things, and general location services Select Companies in Report: ' 3M Company' Alcatel-Lucent' iSIGN' LG' Nokia' Samsung' Qualcomm' Verizon Wireless
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This document provides a summary and table of contents for a 900-page report analyzing the clinical chemistry and immunodiagnostic markets in five major European countries. The report explores trends, evaluates competitors, and identifies opportunities in these evolving markets. It contains estimates of test volumes, sales forecasts by category and country, and competitive profiles of leading suppliers.
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
This document is a report on the China iron ore mining industry in 2013. It provides an overview of the industry, including its definition and development history. It analyzes the macroeconomic environment and discusses factors like policy, upstream/downstream industries. It also examines the international and domestic markets. Key data on the industry from 2008-2012 is presented, including numbers of enterprises, employees, assets, output, sales, profits and trade. The competitive landscape and strategies of major companies are evaluated. The report concludes with discussions of development trends, investment environment and new technologies in the industry.
This document provides a summary and table of contents of the "World Biomass Report" published in November 2012. The report examines the global biomass market and finds that while it suffered during the economic downturn due to low coal prices and supply issues, the sector began growing again in 2010 as coal prices rose. Most biomass plants rely on wood pellets imported from North America, though suppliers from other regions like Russia and Australia aim to compete in the market. The full report contains detailed information on biomass resources, technologies, logistics, investments and policies on a global and national level.
This report provides an overview of the global biofuels industry in 2012. It summarizes production and policies related to first, second, and third generation biofuels in countries around the world. The report finds that 2009 was a difficult year for the biofuels industry due to low oil prices and reduced demand. However, projects using diverse feedstocks or next generation technologies like cellulosics and algae continued to receive investment. The report includes sections on biofuel production trends, technologies, environmental impacts, and policies in regions like Europe, the USA, and individual European countries.
This report analyzes the current state of various renewable energy technologies including hydropower, wind, solar, biomass, biofuels, and geothermal. It examines the market size and outlook for each technology by region, discusses the advantages and disadvantages of different renewable sources, and assesses the development status and future potential of the renewable energy industry globally. The report also profiles major renewable energy companies and evaluates government policies and industry support programs around the world.
This report provides an overview of the global solar photovoltaic (PV) market. It outlines key industry data like global solar capacity, production figures, and forecasts for future growth. It also examines major country markets and discusses the advantages, challenges, and components of the solar PV industry. The report analyzes factors such as government incentives, technology developments, and manufacturing trends that are shaping the future of the solar industry.
Inguinal Hernia Global Clinical Trials Review, H1, 2013ReportLinker.com
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Inguinal Hernia Global Clinical Trials Review, H1, 2013" provides data on the Inguinal Hernia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inguinal Hernia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Inguinal Hernia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Cancer Cachexia Global Clinical Trials Review, H1, 2013" provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Cachexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Pompe Disease Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report on clinical trials for Pompe disease from January 2013. It provides an overview of the number and location of trials worldwide in the first half of 2013. The US, Germany, and China had the most trials. The trials were mostly in late phases and investigated drugs from companies like Genzyme and Sanofi. The report analyzed trial trends over time and provided profiles of top trial sponsors.
Pompe Disease Global Clinical Trials Review, H1, 2013
Statins: World Market Outlook 2011-2021
1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Statins: World Market Outlook 2011-2021
Published on March 2011
Report Summary
What will happen now in the statin drugs market'
What does the future hold for the statins industry and market' Our new report shows how the patent expiry of Lipitor and others will
affect statin drug revenues from 2011 onwards.
Our report gives you revenue forecasts for statin drugs from 2011 to 2021. We aim to save you time and aid your decisions through
our research, data and discussions. By ordering now, you can stay ahead.
In 2009 the world statins market generated over $27bn in revenues. We show the organisations, products and activities that will
shape the statins industry and market this decade.
What revenues will statin drug forms achieve from 2011 to 2021' What revenues can leading products - such as Lipitor and Crestor -
achieve' What revenue trends will national markets show' How will generic sales take off'
Our new study answers those questions and many others for lipid-lowering drugs. We show you what companies are doing, and how
branded and generic competition is shaping up.
From 2011 to 2021 the patent expiries of Lipitor (atorvastatin) and Crestor (rosuvastatin) will lead to rising generic competition. The
overall branded statins market looks set to decline. We show you by how much, and where generic and novel drug opportunities will
be.
Our report gives you revenue forecasts at world, group, product and national levels. You will also see trends in dyslipidemia R&D. We
analyse opportunities in coronary heart disease.
Here, you can find data, analyses and opinion to benefit your research, calculations, meetings and presentations. Please respond
now to get that information.
Analysis and expert opinion to help your work - so you won't be left behind
Our report gives you revenue forecasts, growth rates, market shares, SWOT analysis, an R&D review and expert opinion. We include
80 tables and charts and two research interviews (shown in the accompanying lists).
We can help you now, making it easier for you to stay ahead in this market.
Statins: World Market Outlook 2011-2021 shows you revenue trends, opportunities and challenges
Our report gives you the following advantages:
' You will find hard data for the statins industry and market - seeing revenue trends
' You will receive revenue forecasts for the global lipid-lowering drug market to 2021 - with statin and non-statin groups represented
' You will find revenues for original-brand and generic statins from 2009 to 2021, with discussions of market potential and competition
Statins: World Market Outlook 2011-2021 (From Slideshare) Page 1/12
2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
' You will discover revenue forecasts for atorvastatin, rosuvastatin, simvastatin, pravastatin, fluvastatin, pitavastatin and lovastatin
products to 2021
' You will learn how the patent expiries of Lipitor and Crestor will affect the future of this therapeutic market
' You will receive revenue forecasts for the leading national markets to 2021 (US, Canada, Japan, France, UK, Spain, Italy, Germany,
Brazil, China and India)
' You will examine research and development, as well as up-and-coming products
' You will review under-met needs in the lipid-lowering drug market, with therapeutic requirements and commercial opportunities
discussed
' You will investigate strengths, competition and opportunities that will influence the statins industry and market from 2011 onwards
' You will see what will stimulate and restrain the statins industry and market
' You will analyse opportunities for established companies and those seeking to enter the dyslipidemia treatment market
' You will view expert opinion from our survey, including full interview transcripts
' You will discover where the statins industry and market are heading - technology, competition and revenues.
That mix of quantitative and qualitative market analysis sets our report apart. Our emphasis is on future revenue trends - predictions
found only in our work. Our independent analysis helps you to stay ahead in market knowledge.
You can order our report, receiving the market information you need
Our report can benefit everybody interested in the development, production, sales and marketing of statins and other lipid-lowering
drugs. We give predictions and answers you need. Please order our report now, making sure you don't miss out.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs
Table of Content
Table of Contents
1. Executive Summary
1.1 Review of the World Statins Market
1.2 Aims, Scope and Format of Report
1.3 Research and Analysis Methods
2. Dyslipidaemia and Coronary Heart Disease
2.1 Cholesterol and Triglycerides
2.2 Lipoproteins as Transporters of Cholesterol and Triglycerides
2.3 Dyslipidaemia and Atherosclerosis
2.4 Cholesterol Risk Levels
2.5 The Fredrickson/World Health Organization (WHO) Classification of Dyslipidaemia
2.6 Cardiovascular Disease
2.7 Risk Factors for Coronary Heart Disease
2.8 Cholesterol Testing
2.9 Primary and Secondary Prevention of Atherosclerosis
Statins: World Market Outlook 2011-2021 (From Slideshare) Page 2/12
3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
3. Statins and Other Lipid-Lowering Drugs
3.1 Statins: Types and Mechanism of Action
3.2 Atorvastatin
3.2.1 Atorvastatin Indications
3.2.2 Atorvastatin Brands and Generic Manufacturers
3.3 Rosuvastatin
3.3.1 Rosuvastatin Indications
3.3.2 Rosuvastatin Brands and Generic Manufacturers
3.4 Simvastatin
3.4.1 Simvastatin Indications
3.4.2 Simvastatin Brands and Generic Manufacturers
3.5 Pravastatin
3.5.1 Pravastatin Indications
3.5.2 Pravastatin Brands and Generic Manufacturers
3.6 Fluvastatin
3.6.1 Fluvastatin Indications
3.6.2 Fluvastatin Brands and Generic Manufacturers
3.7 Pitavastatin
3.8 Lovastatin
3.8.1 Lovastatin Indications
3.8.2 Lovastatin Brands and Generic Manufacturers
3.9 Statin/Non-Statin Combination Drugs
3.9.1 Lovastatin/Nicotinic Acid
3.9.2 Simvastatin/Nicotinic Acid
3.9.3 Simvastatin/Ezetimibe
3.9.4 Caduet (atorvastatin/amlodipine)
3.10 Other Lipid-Lowering Drugs
3.10.1 Anion-Exchange Resins
3.10.2 Ezetimibe
3.10.3 Fibrates
3.10.4 Nicotinic Acid
3.10.5 Omega-3-Acid Ethyl Esters
4. Summary of the World Statins Market, 2011-2021
4.1 Overview of the World Statins Market, 2011-2021
4.2 World Statins Market Will See Declining Sales, 2009-2021
4.2.1 The Lipitor Patent Cliff
4.2.2 Pitavastatin Will See Growing Competition from Generic and More-Established Statin Brands
4.3 Generic Products Set to Dominate the World Statins Market
4.4 Statin Drug Markets in India and China Expected to Grow from 2011-2021
5. World Market for Statin Drugs, 2011-2021
5.1 Statins are Leading Therapies in the Lipid-Lowering Market
5.1.1 The World Lipid-Lowering Market
5.1.2 World Lipid-Lowering Drug Market Forecasts, 2009-2021
5.2 The World Statins Market
5.2.1 The World Statins Market, 2009
5.2.2 Scope for Further Growth: World Statins Market Forecasts, 2009-2010
Statins: World Market Outlook 2011-2021 (From Slideshare) Page 3/12
4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
5.2.3 The Impact of Atorvastatin Generics on the World Statins Market, 2011-2015
5.2.4 Opportunities for Generics Manufacturers: World Statins Market Forecasts, 2015-2019
5.2.5 Prospects for the World Statins Market, 2020-2021
5.3 The Branded and Generic Statins Markets
5.3.1 The Branded and Generic Statins Markets, 2009
5.3.2 When Will Sales of Generic Statins Exceed Branded Revenues'
5.4 Statins Market Forecast by Drug Class, 2009-2021
5.4.1 Will Atorvastatin Market Show Continuous Decline in Revenues from 2011-2021'
5.4.2 Revenues of Rosuvastatin and Statin Combination Drugs Expected to Grow from 2011-2015
5.5 Atorvastatin
5.5.1 The Atorvastatin Market, 2009
5.5.2 Atorvastatin Market Forecast, 2009-2021
5.5.3 Lipitor Market Forecast, 2009-2021
5.5.4 Prospects for Lipitor after Patent Expiry: Market Forecast, 2011-2015
5.5.5 Lipitor Market Forecast, 2016-2021
5.5.6 Generic Atorvastatin Market Forecast, 2009-2021
5.6 Rosuvastatin
5.6.1 The Rosuvastatin Market, 2009
5.6.2 Rosuvastatin Market Forecast, 2009-2021
5.6.3 Crestor Market Forecast, 2009-2021
5.6.4 Generic Rosuvastatin Market, 2009-2021
5.7 Simvastatin
5.7.1 The Simvastatin Market, 2009
5.7.2 Simvastatin Market Forecast, 2009-2021
5.7.3 Zocor Market Forecast, 2009-2021
5.7.4 Generic Simvastatin Market, 2009-2021
5.8 Pravastatin
5.8.1 The Pravastatin Market, 2009
5.8.2 Pravastatin Market Forecast, 2009-2021
5.8.3 Mevalotin/Pravachol Market Forecast, 2009-2021
5.8.4 Generic Pravastatin Market, 2009-2021
5.9 Fluvastatin
5.9.1 The Fluvastatin Market, 2009
5.9.2 Fluvastatin Market Forecast, 2009-2021
5.9.3 Lescol/Lochol Market Forecast, 2009-2021
5.9.4 Generic Fluvastatin Market, 2009-2021
5.10 Pitavastatin
5.10.1 The Pitavastatin Market, 2009
5.10.2 Pitavastatin Market Forecast, 2009-2021
5.10.3 Livalo Market Forecast, 2009-2021
5.10.4 Generic Pitavastatin Market, 2009-2021
5.11 Lovastatin
5.11.1 The Lovastatin Market, 2009
5.11.2 Lovastatin Market Forecast, 2009-2021
5.12 Statin/Non-Statin Combination Drugs
5.12.1 The Statin/Non-Statin Combination Market, 2009
5.12.2 Statin Combination Market Will See Positive Growth in Market Size, 2009-2015
5.12.3 Generic Drugs Will Dominate the Statin Combination Market, 2016-2021
Statins: World Market Outlook 2011-2021 (From Slideshare) Page 4/12
5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
5.12.4 Vytorin/Inegy Market Forecast, 2009-2021
5.12.5 Caduet Market Forecast, 2009-2021
6. Leading National Markets for Statin Drugs, 2011-2021
6.1 Leading National Markets for Sales of Statins, 2009
6.2 Sales Forecasts for the Leading National Markets, 2009-2021
6.2.1 The Statins Market in the US, 2009-2021
6.2.2 The Statins Market in Japan, 2009-2021
6.2.3 The Statins Market in Canada, 2009-2021
6.2.4 The Leading European Statins Markets, 2009-2021
6.2.5 The Statins Markets in India and China, 2009-2021
6.2.6 The Statins Market in Brazil, 2009-2021
7. Analysis of Factors Influencing the World Statins Market, 2011-2021
7.1 SWOT Analysis of World Statins Market
7.2 Drivers for and Restraints on Market Growth7.2.1 Market Drivers
7.2.2 Market Restraints
7.3 Outlook for the World Statins Market, 2011-2021
7.3.1 Genericisation of the World Statins Market Will be a Restraint on Market Growth
7.3.2 Governments and Insurers Will Favour Generic Statins
7.3.3 Emerging Economies of India and China Will See Growth in Statin Sales
7.4 Patient Compliance for Statin Medications
7.4.1 Patients Exhibit Poor Compliance for Statin Medications
7.4.2 Effective Contact between Patients and Healthcare Practitioners is the Key to Improving Patient Compliance
7.5 Safety of Statins
7.6 Statin OTC Switching
7.6.1 Rationale for OTC Switching
7.6.2 Statin OTC Switching in the UK
7.6.3 Statin OTC Switching in the US
7.6.4 What are the Prospects for Worldwide Statin OTC Switching'
7.7 The Role of Clinical Trials in Expanding the Size of the World Statins Market
8. Research Interviews
8.1 Interview with Dr Humayun J. Chaudhry, Commissioner of Health Services, Suffolk County, New York, USA
8.1.1 Improving Patient Compliance in Statin Therapy
8.1.2 The Future of Cholesterol Testing
8.1.3 Web-Based Information Technology
8.2 Interview with Professor Naveed Sattar, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, UK
8.2.1 Current Research on the Therapeutic Effects of Statin Drugs
8.2.2 Prospects for the Lipid-Lowering Drug Market after Lipitor Loses Patent Protection in 2011
8.2.3 R&D Prospects within the Lipid-Lowering Field
8.2.4 The Statin Pipeline
9. Statin and Non-Statin Lipid-Lowering R&D Pipeline
9.1 The Statin R&D Pipeline Lacks New Single Statin Drugs
9.2 Will CETP Inhibitors Succeed Statins as Blockbuster Drugs in the Lipid-Lowering Market'
9.3 Statin/Non-Statin Combination Lipid-Lowering Pipeline
9.3.1 Simvastatin/Fenofibrate
Statins: World Market Outlook 2011-2021 (From Slideshare) Page 5/12
6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
9.3.2 Simvastatin/Rosiglitazone
9.4 The Non-Statin Lipid-Lowering Pipeline
9.4.1 Eicosapentaenoic Acid/Docosahexanoic Acid
9.4.2 Eprotirome
9.4.3 Anacetrapib
9.4.4 Dalcetrapib
9.4.5 Darapladib
10. Conclusions
10.1 Statins Will Remain Vital Therapies for Treating Dyslipidaemia
10.2 Future Challenges for the Statin Industry
10.2.1 What are the Consequences of a Weak Statin R&D Pipeline'
10.2.2 Increasing Patient Compliance is Vital for the Sustained Growth of the Statins Market
10.3 By 2017, Sales of Generic Statins Will Outperform those of Branded Statins
10.4 Emerging Markets of India and China Will See Growth in Statin Sales
List of Tables
Table 2.1 Risk Levels for Total Cholesterol, 2011
Table 2.2 Risk Levels for LDL Cholesterol, 2011
Table 2.3 Risk Levels for HDL Cholesterol, 2011
Table 2.4 Risk Levels for Triglycerides, 2011
Table 2.5 The Fredrickson/WHO Classification Scheme for Dyslipidaemia, 2011
Table 3.1 Leading Manufacturers of Generic Simvastatin, 2011
Table 3.2 Leading Manufacturers of Generic Pravastatin, 2011
Table 3.3 Leading Manufacturers of Generic Lovastatin, 2011
Table 4.1 Statin Lipid-Lowering Market Revenues ($bn) and Shares ($bn, %), 2009-2015
Table 4.2 Statin Lipid-Lowering Market Revenues ($bn) and Shares ($bn, %), 2016-2021
Table 4.3 Branded and Generic Statins: Market Revenues ($bn), 2009-2021
Table 5.1 World Lipid-Lowering Market Revenues ($bn), 2009
Table 5.2 World Sales ($bn) and Market Shares ($bn, %) for the Non-Statin Lipid-Lowering Market, 2009
Table 5.3 World Lipid-Lowering Market Revenues ($bn), 2009-2015
Table 5.4 World Lipid-Lowering Market Revenues ($bn), 2016-2021
Table 5.5 Revenues ($bn) of Leading Statins by Active Ingredient and Brand Names, 2009
Table 5.6 Branded and Generic Statins: Market Revenues ($bn), 2009 and 2021
Table 5.7 Branded and Generic Statins: Market Revenues ($bn), 2009-2015
Table 5.8 Branded and Generic Statins: Market Revenues ($bn), 2016-2021
Table 5.9 Statins Market Revenues ($bn) by Drug Class, 2009-2015
Table 5.10 Statins Market Revenues ($bn) by Drug Class, 2016-2021
Table 5.11 Atorvastatin Drug Revenues ($bn) and Market Shares ($bn, %), 2009
Table 5.12 Atorvastatin Drug Revenues ($bn), 2009-2015
Table 5.13 Atorvastatin Drug Revenues ($bn), 2016-2021
Table 5.14 Rosuvastatin Drug Revenues ($bn) and Market Shares ($bn, %), 2009
Table 5.15 Rosuvastatin Drug Revenues ($bn), 2009-2015
Table 5.16 Rosuvastatin Drug Revenues ($bn), 2016-2021
Table 5.17 Simvastatin Drug Revenues ($bn) and Market Shares ($bn, %), 2009
Table 5.18 Simvastatin Drug Revenues ($bn), 2009-2015
Table 5.19 Simvastatin Drug Revenues ($bn), 2016-2021
Statins: World Market Outlook 2011-2021 (From Slideshare) Page 6/12
7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table 5.20 Pravastatin Drug Revenues ($bn) and Market Shares ($bn, %), 2009
Table 5.21 Pravastatin Drug Revenues ($bn), 2009-2015
Table 5.22 Pravastatin Drug Revenues ($bn), 2016-2021
Table 5.23 Fluvastatin Drug Revenues ($bn) and Market Shares ($bn, %), 2009
Table 5.24 Fluvastatin Drug Revenues ($bn), 2009-2015
Table 5.25 Fluvastatin Drug Revenues ($bn), 2016-2021
Table 5.26 Pitavastatin Drug Revenues ($bn) and Market Shares ($bn, %), 2009
Table 5.27 Pitavastatin Drug Revenues ($bn), 2009-2015
Table 5.28 Pitavastatin Drug Revenues ($bn), 2016-2021
Table 5.29 Lovastatin Drug Revenues ($bn), 2009-2015
Table 5.30 Lovastatin Drug Revenues ($bn), 2016-2021
Table 5.31 Statin/Non-Statin Combination Drug Revenues ($bn) and Market Shares ($bn, %), 2009
Table 5.32 Statin/Non-Statin Combination Drug Revenues ($bn), 2009-2015
Table 5.33 Statin/Non-Statin Combination Drug Revenues ($bn), 2016-2021
Table 6.1 Revenues ($bn) of Statins in Leading National Markets, 2009
Table 6.2 Statins Revenues ($bn) in Leading National Markets, 2009-2015
Table 6.3 Statins Revenues ($bn) in Leading National Markets, 2016-2021
Table 7.1 SWOT Analysis of the Statins Market, 2011
Table 7.2 Expected Patent Expiries of Statins, 2009-2021
Table 9.1 Prominent Statin and Non-Statin Lipid-Lowering Agents in the R&D Pipeline, 2011
List of Figures
Figure 4.1 Lipitor Revenues ($bn), 2009-2021
Figure 4.2 Branded and Generic Statins: Market Revenues ($bn), 2009-2021
Figure 5.1 Market Share ($bn, %) in the Lipid-Lowering Market, 2009
Figure 5.2 World Lipid-Lowering Market Revenues ($bn), 2009-2021
Figure 5.3 Statin Market Shares ($bn, %) by Active Ingredient, 2009
Figure 5.4 Statin Market Shares ($bn, %) by Leading Brand, 2009
Figure 5.5 World Statin Market Revenues ($bn), 2009-2021
Figure 5.6 Branded and Generic Statins: Market Revenues ($bn), 2009-2021
Figure 5.7 Statins Market Revenues ($bn) by Drug Class, 2009-2021
Figure 5.8 Statins Market Shares ($bn, %) by Drug Class, 2009
Figure 5.9 Statins Market Shares ($bn, %) by Drug Class, 2015
Figure 5.10 Statins Market Shares ($bn, %) by Drug Class, 2021
Figure 5.11 Atorvastatin Drug Revenues ($bn), 2009-2021
Figure 5.12 Rosuvastatin Drug Revenues ($bn), 2009-2021
Figure 5.13 Simvastatin Drug Revenues ($bn), 2009-2021
Figure 5.14 Pravastatin Drug Revenues ($bn), 2009-2021
Figure 5.15 Fluvastatin Drug Revenues ($bn), 2009-2021
Figure 5.16 Pitavastatin Drug Revenues ($bn), 2009-2021
Figure 5.17 Lovastatin Drug Revenues ($bn), 2009-2021
Figure 5.18 Statin/Non-Statin Combination Drug Revenues ($bn), 2009-2021
Figure 6.1 Statin Drug Revenues ($bn) in Leading National Markets, 2009
Figure 6.2 Market Shares ($bn, %) of the World Statins Market by Country, 2009
Figure 6.3 The US Statins Market ($bn), 2009-2021
Figure 6.4 Market Shares ($bn, %) of the World Statins Market by Country, 2021
Figure 6.5 The Japanese Statins Market ($bn), 2009-2021
Statins: World Market Outlook 2011-2021 (From Slideshare) Page 7/12
8. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Figure 6.6 The Canadian Statins Market ($bn), 2009-2021
Figure 6.7 The Leading European Statins Markets ($bn), 2009-2021
Figure 6.8 Statins Markets ($bn) in India and China, 2009-2021
Figure 6.9 The Brazilian Statins Market ($bn), 2009-2021
Figure 10.1 Branded and Generic Statins: Revenues ($bn), 2009-2021
Companies Listed
Abbott
Actavis
Almirall
Alter
American Heart Association
American Medical Association
Apotex
Astellas
AstraZeneca
Bagó
Bristol-Myers Squibb
British Heart Foundation Glasgow Cardiovascular Centre
Chiesi
CINFA
Cholesterol Treatment Trialists' Collaboration
Choongwae
Cobalt Laboratories
Cobalt Pharmaceuticals
Cochrane Library
Covidien
Daiichi Sankyo
Dr. Reddy's Laboratories
Eli Lilly
Esteve
European Medicines Agency (EMA)
European Society of Cardiology
Ferrer
Food and Drug Administration (FDA)
Forest Laboratories
Gedeon Richter
Genzyme
GlaxoSmithKline (GSK)
Glenmark
Human Genome Sciences
Intas
Japan Tobacco
Johnson & Johnson
Karo Bio
Kowa Pharmaceuticals
Krka
Statins: World Market Outlook 2011-2021 (From Slideshare) Page 8/12
9. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
London School of Hygiene and Tropical Medicine
Lupin
Lundbeck
Medicines and Healthcare Products Regulatory Agency (MHRA)
Medley Pharmaceuticals
Menarini
Merck & Co.
Mitsubishi Tanabe
Mochida Pharmaceutical
Mylan
National Health Service (NHS)
National Heart Lung and Blood Institute (NHLBI)
National Institute for Clinical Excellence (NICE)
National Institutes of Health (NIH)
Nissan Chemical
Nichi-Iko
Novartis
Omthera
Par Pharmaceutical
Pfizer
Pierre Fabre
Polypharma
Public Citizen
Ranbaxy Laboratories
Ratiopharm
Recordati Pharmaceuticals
Roche
Sandoz
Sanofi-Aventis
Sawai
Sunovion
Servier
Schering-Plough
Shionogi & Co.
Sigma Pharmaceuticals
Sigma-Tau Pharmaceuticals
Solvay
Stada
Takeda
Teva Pharmaceuticals
University of Birmingham
University of Bristol
University of Glasgow
University of Oxford
Watson Pharmaceuticals
World Health Organization (WHO)
Wyeth
Zentiva
Statins: World Market Outlook 2011-2021 (From Slideshare) Page 9/12
10. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Zydus Cadila
Statins: World Market Outlook 2011-2021 (From Slideshare) Page 10/12
11. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Statins: World Market Outlook 2011-2021
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 2 496.90 Quantity: _____
Department License--USD 4 995.25 Quantity: _____
Site License--USD 8 325.90 Quantity: _____
Corporate License--USD 11 656.55 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Statins: World Market Outlook 2011-2021 (From Slideshare) Page 11/12
12. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Statins: World Market Outlook 2011-2021 (From Slideshare) Page 12/12